John Frelinger
| Title | Professor |
|---|
| Institution | School of Medicine and Dentistry |
|---|
| Department | Microbiology and Immunology |
|---|
| Address | University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester NY 14642
|
|---|
|
|
|
| 1971 |
-
| 1975 | National Merit Scholarship | | 1975 |
|
| B.S. with Distinction and Departmental Honors | | 1981 |
-
| 1983 | Jane Coffin Childs Fellowship | | 1983 |
-
| 1984 | American Cancer Society Senior Fellowship, California Division | | 1986 |
-
| 1988 | Junior Faculty Research Award | American Cancer Society | | 1991 |
-
| 1993 | Andrew W. Mellon Deans Teaching Scholar | Excellence in Teaching and Research | | 1994 |
|
| Special Commendation Teaching-Medical School | | 1995 |
|
| Herbert W. Mapstone Prize for Teaching Excellence | | 1996 |
|
| Special Commendation Teaching-Medical School | | 1998 |
|
| Herbert W. Mapstone Prize for Teaching Excellence | | 2000 |
|
| Faculty Speaker, Medical School Class of 2000 Awards Ceremony | | 2000 |
|
| Distinguished Speaker | | 2002 |
|
| Special Commendation Teaching-Medical School | | 2011 |
-
| 2014 | AAI Education Committee | American Association of Immunologists | | 2012 |
|
| Alumni Gold Medal Teaching Award |
My laboratory has a number of interests united by the common theme of T cell recognition. One focus of research has been the generation and maintenance of effective T cell responses to tumors. It has become apparent that anti-tumor responses can be directed against differentiation antigens. Thus, even with multiple mechanisms of establishing and maintaining tolerance, tolerance is not absolute. We hypothesize that it is possible to direct an effective response against tumors by inducing an autoimmune response to organ-specific antigens. To examine this hypothesis, we will use transgenic mice lines we have developed which specifically express human PSA in the prostate and investigate how this expression affects their ability to generate CTL responses to human PSA using novel immunization strategies. In this light, we have been working on developing novel viral vectors for immunization. Helper free herpes amplicons, plasmid based vectors that have an extremely large coding capacity, are attractive viral vaccine candidates for expressing recombinant proteins in vivo for immunization. The amplicon system has particular promise since it encodes no viral gene products and we have shown it very effectively infects dendritic cells. In collaboration with Edith Lord and in conjunction with Tom Foster's laboratory in the Department of Imaging Sciences, we have devised imaging approaches to look at the early steps in immunization and at the effector T cells generated. These studies will contribute to the rational design of immunotherapy for tumors as well as for HIV. We also believe that many of the techniques and approaches will be applicable to other infectious agents as well. In this regard, we are collaborating with investigators at University of North Carolina to identify T cell epitopes of Francisella tularensis. Francisella tularensis (FT) is a gram negative bacterium that is able to infect a wide range of mammalian hosts. FT has several properties that suggest could be developed as a biological weapon, including its ability to be aerosolized and its low LD50. Indeed, it has been asserted that FT was used as a bioweapon in World War II. Unfortunately relatively little information is available concerning the detailed cellular mechanism of resistance to re-infection either in humans or in experimental animals. However, as expected for a pathogen that grows largely intracellularly, T cells are believed to be a critical component in resistance to reinfection and recovery from primary infection. My laboratory has developed a technique called the TCAD ( the T-Cell antigen discovery technique) to identify and improve T cell epitopes, originally in the context of tumor vaccines. We have recently modified this system to large-scale screens for the identification of T cell epitopes from FT using this system which takes advantage of the tremendously enhanced efficiency particulate antigen cross-priming and a novel reporter system of T cell activation. It is hoped that the identification of the T cell epitopes recognized will yield to a batter understanding of the nature of a protective response and ultimately a defined vaccine.
-
Valentino MD, Abdul-Alim CS, Maben ZJ, Skrombolas D, Hensley LL, Kawula TH, Dziejman M, Lord EM, Frelinger JA, Frelinger JG. A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens. J Immunol Methods. 2011 Oct 28; 373(1-2):111-26.
-
Puskas J, Skrombolas D, Sedlacek A, Lord E, Sullivan M, Frelinger J. Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases. Immunology. 2011 Jun; 133(2):206-20.
-
Valentino MD, Maben ZJ, Hensley LL, Woolard MD, Kawula TH, Frelinger JA, Frelinger JG. Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets. Immunology. 2011 Mar; 132(3):348-60.
-
Sorensen EW, Gerber SA, Frelinger JG, Lord EM. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J Immunol. 2010 Feb 15; 184(4):1858-66.
-
Valentino MD, Hensley LL, Skrombolas D, McPherson PL, Woolard MD, Kawula TH, Frelinger JA, Frelinger JG. Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS. Mol Immunol. 2009 May; 46(8-9):1830-8.
-
Valentino M, Frelinger J. An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensis. Immunol Res. 2009; 45(2-3):218-28.
-
Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008 Mar 1; 180(5):3132-9.
-
Santos K, Simon DA, Conway E, Bowers WJ, Mitra S, Foster TH, Lugade A, Lord EM, Federoff HJ, Dewhurst S, Frelinger JG. Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors. Hum Gene Ther. 2007 Feb; 18(2):93-105.
-
Ramanayake T, Simon DA, Frelinger JG, Lord EM, Robert J. In vivo study of T-cell responses to skin alloantigens in Xenopus using a novel whole-mount immunohistology method. Transplantation. 2007 Jan 27; 83(2):159-66.
-
Malboeuf CM, Simon DA, Lee YE, Lankes HA, Dewhurst S, Frelinger JG, Rose RC. Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine. 2007 Apr 30; 25(17):3270-6.
-
Mitra S, Cassar SE, Niles DJ, Puskas JA, Frelinger JG, Foster TH. Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha. Mol Cancer Ther. 2006 Dec; 5(12):3268-74.
-
Santos K, Duke CM, Rodriguez-Colon SM, Dakwar A, Fan S, Keefer MC, Federoff HJ, Frelinger JG, Bowers WJ, Dewhurst S. Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. Vaccine. 2007 Feb 19; 25(9):1634-46.
-
Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol. 2006 Nov; 169(5):1739-52.
-
Wagner VE, Frelinger JG, Barth RK, Iglewski BH. Quorum sensing: dynamic response of Pseudomonas aeruginosa to external signals. Trends Microbiol. 2006 Feb; 14(2):55-8.
-
Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005 Jun 15; 174(12):7516-23.
-
Gerber SA, Turner MJ, Lugade AA, Moran JP, Frelinger JG, Lord EM. Characterization of a lymph node within the mouse prostate: Detailed analysis using whole mount histology. Prostate. 2005 May 1; 63(2):105-16.
-
Bigelow CE, Vishwasrao HD, Frelinger JG, Foster TH. Imaging enzyme activity with polarization-sensitive confocal fluorescence microscopy. J Microsc. 2004 Jul; 215(Pt 1):24-33.
-
Mitra S, Goren EM, Frelinger JG, Foster TH. Activation of heat shock protein 70 promoter with meso-tetrahydroxyphenyl chlorin photodynamic therapy reported by green fluorescent protein in vitro and in vivo. Photochem Photobiol. 2003 Dec; 78(6):615-22.
-
Moran JP, Gerber SA, Martin CA, Frelinger JG, Lord EM. Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity. Int J Cancer. 2003 Sep 20; 106(5):690-8.
-
Gerber SA, Moran JP, Frelinger JG, Frelinger JA, Fenton BM, Lord EM. Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. Br J Cancer. 2003 May 6; 88(9):1453-61.
-
Fisher TL, Nocera M, Willis RA, Turner MJ, Abdul Alim CS, Brown DM, Bourne PA, di Sant'Agnese PA, Messing EM, Lord EM, Frelinger JG. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors. Prostate. 2002 May 15; 51(3):153-65.
-
Patel D, Frelinger J, Goudsmit J, Kim B. In vitro assay for site-specific proteases using bead-attached GFP substrate. Biotechniques. 2001 Nov; 31(5):1194, 1196, 1198 passim.
-
Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, Federoff HJ, Lord EM, Frelinger JG. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther. 2001 Oct 10; 12(15):1867-79.
-
Turner MJ, Abdul-Alim CS, Willis RA, Fisher TL, Lord EM, Frelinger JG. T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes. J Immunol Methods. 2001 Oct 1; 256(1-2):107-19.
-
Brown DM, Fisher TL, Wei C, Frelinger JG, Lord EM. Tumours can act as adjuvants for humoral immunity. Immunology. 2001 Apr; 102(4):486-97.
-
Greenwood R, Frelinger J. Mechanisms of unresponsiveness: T- and B-cell mediated mechanisms of anergy. Adv Exp Med Biol. 2001; 489:109-17.
-
Skrincosky D, Willis RA, Hocknell PK, Frelinger JG, Mirandola P, Wang X, Dewhurst S. Epitope mapping of human herpesvirus-7 gp65 using monoclonal antibodies. Arch Virol. 2001; 146(9):1705-22.
-
Wu YP, McMahon E, Kraine MR, Tisch R, Meyers A, Frelinger J, Matsushima GK, Suzuki K. Distribution and characterization of GFP(+) donor hematogenous cells in Twitcher mice after bone marrow transplantation. Am J Pathol. 2000 Jun; 156(6):1849-54.
-
Egan RM, Yorkey C, Black R, Loh WK, Stevens JL, Storozynsky E, Lord EM, Frelinger JG, Woodward JG. In vivo behavior of peptide-specific T cells during mucosal tolerance induction: antigen introduced through the mucosa of the conjunctiva elicits prolonged antigen-specific T cell priming followed by anergy. J Immunol. 2000 May 1; 164(9):4543-50.
-
Lee J, Moran JP, Fenton BM, Koch CJ, Frelinger JG, Keng PC, Lord EM. Alteration of tumour response to radiation by interleukin-2 gene transfer. Br J Cancer. 2000 Feb; 82(4):937-44.
-
Conway TF, Sabel MS, Sugano M, Frelinger JG, Egilmez NK, Chen F, Bankert RB. Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum. J Immunol Methods. 2000 Jan 13; 233(1-2):57-65.
-
Martin BK, Frelinger JG, Ting JP. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. J Immunol. 1999 Jun 1; 162(11):6663-70.
-
Storozynsky E, Woodward JG, Frelinger JG, Lord EM. Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells. Immunology. 1999 May; 97(1):138-49.
-
Ostberg JR, Barth RK, Frelinger JG. The Roman god Janus: a paradigm for the function of CD43. Immunol Today. 1998 Dec; 19(12):546-50.
-
Hunt JP, Hunter CT, Brownstein MR, Giannopoulos A, Hultman CS, deSerres S, Bracey L, Frelinger J, Meyer AA. The effector component of the cytotoxic T-lymphocyte response has a biphasic pattern after burn injury. J Surg Res. 1998 Dec; 80(2):243-51.
-
Wei C, Callahan BP, Turner MJ, Willis RA, Lord EM, Barth RK, Frelinger JG. Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes. Int J Mol Med. 1998 Oct; 2(4):487-96.
-
Yeh KY, McAdam AJ, Pulaski BA, Shastri N, Frelinger JG, Lord EM. IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes. J Immunol. 1998 Jun 15; 160(12):5773-80.
-
Lord EM, Yeh KY, Moran JA, Storozynsky E, Frelinger JG. IL-3-mediated enhancement of particulate antigen presentation by macrophages. J Immunother. 1998 May; 21(3):205-10.
-
Lord EM, Frelinger JG. Tumor immunotherapy: cytokines and antigen presentation. Cancer Immunol Immunother. 1998 Apr; 46(2):75-81.
-
Hunt JP, Hunter CT, Brownstein M, Hultman CS, deSerres S, Bracey L, Frelinger J, Meyer AA. Host priming, not target antigen type, decides rejection rate in mice primed with MHC II "knockout" cultured keratinocytes. J Surg Res. 1998 Apr; 76(1):32-6.
-
Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res. 1998 Apr 1; 58(7):1478-85.
-
Willis RA, Wei C, Turner MJ, Callahan BP, Pugh AE, Barth RK, Lord EM, Frelinger JG. A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review). Int J Mol Med. 1998 Feb; 1(2):379-86.
-
Ostberg JR, Dragone LL, Borrello MA, Phipps RP, Barth RK, Frelinger JG. Expression of mouse CD43 in the B cell lineage of transgenic mice causes impaired immune responses to T-independent antigens. Eur J Immunol. 1997 Sep; 27(9):2152-9.
-
Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci U S A. 1997 Jun 10; 94(12):6369-74.
-
McEvoy LM, Sun H, Frelinger JG, Butcher EC. Anti-CD43 inhibition of T cell homing. J Exp Med. 1997 Apr 21; 185(8):1493-8.
-
Ostberg JR, Dragone LL, Driskell T, Moynihan JA, Phipps R, Barth RK, Frelinger JG. Disregulated expression of CD43 (leukosialin, sialophorin) in the B cell lineage leads to immunodeficiency. J Immunol. 1996 Dec 1; 157(11):4876-84.
-
Wei C, Storozynsky E, McAdam AJ, Yeh KY, Tilton BR, Willis RA, Barth RK, Looney RJ, Lord EM, Frelinger JG. Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes. Cancer Immunol Immunother. 1996 Jul; 42(6):362-8.
-
Pulaski BA, Yeh KY, Shastri N, Maltby KM, Penney DP, Lord EM, Frelinger JG. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc Natl Acad Sci U S A. 1996 Apr 16; 93(8):3669-74.
-
McAdam AJ, Pulaski BA, Storozynsky E, Yeh KY, Sickel JZ, Frelinger JG, Lord EM. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol. 1995 Oct 15; 165(2):183-92.
-
Yeh KY, Pulaski BA, Woods ML, McAdam AJ, Gaspari AA, Frelinger JG, Lord EM. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell Immunol. 1995 Oct 15; 165(2):217-24.
-
McAdam AJ, Pulaski BA, Harkins SS, Hutter EK, Lord EM, Frelinger JG. Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells. Int J Cancer. 1995 May 29; 61(5):628-34.
-
Dragone LL, Barth RK, Sitar KL, Disbrow GL, Frelinger JG. Disregulation of leukosialin (CD43, Ly48, sialophorin) expression in the B-cell lineage of transgenic mice increases splenic B-cell number and survival. Proc Natl Acad Sci U S A. 1995 Jan 17; 92(2):626-30.
-
McAdam AJ, Felcher A, Woods ML, Pulaski BA, Hutter EK, Frelinger JG, Lord EM. Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes. J Immunother Emphasis Tumor Immunol. 1994 Apr; 15(3):155-64.
-
Woods ML, McAdam AJ, Frelinger JG, Lord EM. Isolation and expansion of tumor-infiltrating lymphocytes. Biotechniques. 1993 Dec; 15(6):970-2.
-
McAdam AJ, Yeh KY, Pulaski BA, Frelinger JG, Lord EM. Interleukin-3 inhibits the generation of nonspecific killers by interleukin-2. J Immunother Emphasis Tumor Immunol. 1993 Nov; 14(4):293-7.
-
Lord E, McAdam A, Felcher A, Woods M, Pulaski B, Hutter E, Frelinger J. Transfection of TGF-beta producing tumors with IL-2 elicits tumor rejection. Ann N Y Acad Sci. 1993 Aug 12; 690:346-8.
-
McAdam A, Pulaski B, Harkins S, Hutter E, Frelinger J, Lord E. Coexpression of IL-2 and gamma-IFN enhances tumor immunity. Ann N Y Acad Sci. 1993 Aug 12; 690:349-51.
-
Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, Frelinger JG. Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res. 1993 May 1; 53(9):2112-7.
-
Gaspari AA, Ferbel B, Frelinger JG. Thy 1+ dendritic epidermal cells but not Langerhans cells express Ly 48. J Invest Dermatol. 1993 Mar; 100(3):247-53.
-
Baecher-Allan CM, Kemp JD, Dorfman KS, Barth RK, Frelinger JG. Differential epitope expression of Ly-48 (mouse leukosialin). Immunogenetics. 1993; 37(3):183-92.
-
McAdam AJ, Blieden TM, Frelinger JG, Lord EM. CD4-class II major histocompatibility complex interaction does not enhance killing by a class I-restricted CD4+CD8+ cytotoxic T cell clone. Eur J Immunol. 1992 Sep; 22(9):2461-4.
-
Cerosaletti KM, Woodward JG, Lord EM, Frelinger JG. Two regions of the H-2 Dd promoter are responsive to dimethylsulfoxide in line 1 cells by a mechanism distinct from IFN-gamma. J Immunol. 1992 Feb 15; 148(4):1212-21.
-
Dragone L, Pallant A, Insel R, Frelinger JG. CD43 is expressed normally on Wiskott-Aldrich-derived lymphocytes. Exp Clin Immunogenet. 1992; 9(3):130-40.
-
Blieden TM, McAdam AJ, Frelinger JG, Lord EM. Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J Immunol. 1991 Aug 15; 147(4):1433-8.
-
Lombardi G, Matsui M, Moots R, Aichinger G, Sidhu S, Batchelor R, McMichael AJ, Frelinger J, Lechler R. Structural relationship between HLA-A2-restricted and anti-A2 allospecific T-cell recognition: analysis by mutation of the codons for polymorphic and conserved residues. Transplant Proc. 1991 Feb; 23(1 Pt 1):446-8.
-
Lombardi G, Matsui M, Moots R, Aichinger G, Sidhu S, Batchelor R, Frelinger J, Lechler R. Limited regions of the alpha 2-domain alpha-helix control anti-A2 allorecognition: an analysis using a panel of A2 mutants. Immunogenetics. 1991; 34(3):149-56.
-
Blieden TM, McAdam AJ, Foresman MD, Cerosaletti KM, Frelinger JG, Lord EM. Class-I MHC expression in the mouse lung carcinoma, line 1: a model for class-I inducible tumors. Int J Cancer Suppl. 1991; 6:82-9.
-
Dorfman KS, Litaker W, Baecher CM, Frelinger JG. The nucleotide sequence of Ly 48 (mouse leukosialin, sialophorin): the mouse homolog of CD43. Nucleic Acids Res. 1990 Aug 25; 18(16):4932.
-
Phipps RP, Baecher C, Frelinger JG, Penney DP, Keng P, Brown D. Differential expression of interleukin 1 alpha by Thy-1+ and Thy-1- lung fibroblast subpopulations: enhancement of interleukin 1 alpha production by tumor necrosis factor-alpha. Eur J Immunol. 1990 Aug; 20(8):1723-7.
-
Pallant A, Fukuda M, Frelinger JG. CD43 (leukosialin, sialophorin, large sialoglycoprotein) can be expressed in both normal and Wiskott-Aldrich fibroblasts via transfection of a leukosialin cDNA. Eur J Immunol. 1990 Jul; 20(7):1423-8.
-
Cerosaletti KM, Blieden TM, Harwell LW, Welsh KM, Frelinger JG, Lord EM. Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfection. Cell Immunol. 1990 May; 127(2):299-310.
-
Heath WR, Hurd ME, Murray R, Frelinger J, Sherman LA. Analysis of novel residues of class I involved in recognition by alloreactive T cells. Immunogenetics. 1990; 32(2):138-41.
-
Baecher CM, Dorfman KS, Mattei MG, Frelinger JG. cDNA cloning and localization of the mouse leukosialin gene (Ly48) to chromosome 7. Immunogenetics. 1990; 31(5-6):307-14.
-
Pallant A, Eskenazi A, Mattei MG, Fournier RE, Carlsson SR, Fukuda M, Frelinger JG. Characterization of cDNAs encoding human leukosialin and localization of the leukosialin gene to chromosome 16. Proc Natl Acad Sci U S A. 1989 Feb; 86(4):1328-32.
-
Bahler DW, Cerosaletti KM, Lord EM, Frelinger JG. Molecular analysis of deficient class I H-2 antigen expression by mouse lung carcinoma cells. J Immunol. 1988 Jun 1; 140(11):4003-12.
-
Dennert G, Landon C, Lord EM, Bahler DW, Frelinger JG. Lysis of a lung carcinoma by poly I:C-induced natural killer cells is independent of the expression of class I histocompatibility antigens. J Immunol. 1988 Apr 1; 140(7):2472-5.
-
Baecher CM, Infante AJ, Semcheski KL, Frelinger JG. Identification and characterization of a mouse cell surface antigen with alternative molecular forms. Immunogenetics. 1988; 28(5):295-302.
-
Bahler DW, Frelinger JG, Harwell LW, Lord EM. Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection. Proc Natl Acad Sci U S A. 1987 Jul; 84(13):4562-6.
-
Sawicki JA, Frelinger JG, Palmer M, Buck DA, Dietzschold B, Wettstein PJ. Identical RT1 class II molecules are expressed by rat RT1m and RT1c haplotypes. J Immunol. 1985 Oct; 135(4):2853-8.
-
Frelinger JG, Shigeta M, Fathman CG. An analysis of monoclonal T cell and antibody recognition sites on Ia molecules. J Invest Dermatol. 1985 Jul; 85(1 Suppl):30s-33s.
-
Frelinger J, Sing A, Infante A, Fathman CG. Clonotypic antibodies which stimulate T cell clone proliferation. Immunol Rev. 1984 Oct; 81:21-38.
-
Frelinger JG, Shigeta M, Infante AJ, Nelson PA, Pierres M, Fathman CG. Multiple functional sites on a single Ia molecule defined using T cell clones and antibodies with chain-determined specificity. J Exp Med. 1984 Mar 1; 159(3):704-15.
-
Stroynowski I, Orn A, Goodenow RS, McMillan M, Forman J, Brayton PR, Frelinger J, Hood L. Cytotoxic T lymphocytes recognize determinants on the BALB/c-H-2Ld molecule controlled by alpha 1 and alpha 2 but not alpha 3 external domains. Immunogenetics. 1984; 20(2):141-54.
-
Fathman CG, Frelinger JG. T-lymphocyte clones. Annu Rev Immunol. 1983; 1:633-55.
-
Beck BN, Frelinger JG, Shigeta M, Infante AJ, Cummings D, Hämmerling G, Fathman CG. T cell clones specific for hybrid I-A molecules. Discrimination with monoclonal anti-I-Ak antibodies. J Exp Med. 1982 Oct 1; 156(4):1186-94.
-
Steinmetz M, Moore KW, Frelinger JG, Sher BT, Shen FW, Boyse EA, Hood L. A pseudogene homologous to mouse transplantation antigens: transplantation antigens are encoded by eight exons that correlate with protein domains. Cell. 1981 Sep; 25(3):683-92.
-
Frelinger JG, Hood L, Wettstein P. Analyses of RT1 products using two-dimensional polyacrylamide gels. Transplant Proc. 1981 Jun; 13(2):1360-3.
-
Wettstein PJ, Frelinger JG, Hood L. Serologic and biochemical analyses of rat class II molecules with anti-Ia sera. Transplant Proc. 1981 Jun; 13(2):1364-6.
-
Steinmetz M, Frelinger JG, Fisher D, Hunkapiller T, Pereira D, Weissman SM, Uehara H, Nathenson S, Hood L. Three cDNA clones encoding mouse transplantation antigens: homology to immunoglobulin genes. Cell. 1981 Apr; 24(1):125-34.
-
Frelinger JG, Frelinger JA, Hood L. Peptide map comparisons of epidermal and spleen H-2 molecules. Immunogenetics. 1981 Mar 1; 12(5-6):569-77.
-
Wettstein PJ, Frelinger JG, Hood L. Serological and biochemical characterization of rat (RT1) class II molecules with restricted mouse anti-Ia sera. Immunogenetics. 1981; 13(1-2):93-107.
-
Frelinger JA, Frelinger JG. Bone marrow origin of Ia molecules purified from epidermal cells. J Invest Dermatol. 1980 Jul; 75(1):68-70.
-
Blankenhorn EP, Cecka JM, Frelinger J, Götze D, Hood L. Structure of Ia antigens from the rat. Mouse alloantisera demonstrate at least two distinct molecular species. Eur J Immunol. 1980 Feb; 10(2):145-51.
-
Frelinger JG, Hood L, Hill S, Frelinger JA. Mouse epidermal Ia molecules have a bone marrow origin. Nature. 1979 Nov 15; 282(5736):321-3.
-
Frelinger JG, Motulsky H, Woodward DO. Effects of Chloramphenicol on the Circadian Rhythm of Neurospora crassa. Plant Physiol. 1976 Oct; 58(4):592-4.
|
Frelinger's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
